Gink­go BioWorks picks up an­tibi­otics ef­fort with Roche where Warp Dri­ve Bio left off

When Rev­o­lu­tion Med­i­cines ab­sorbed fel­low Third Rock start­up Warp Dri­ve Bio in­to its op­er­a­tions last Oc­to­ber — then new­ly tran­si­tioned from an­ti­fun­gal to on­col­o­gy — the ex­ec team was still re­view­ing op­tions for the genome min­ing plat­form, which was the sub­ject of a deal with Roche.

They found a buy­er in Gink­go BioWorks, a spe­cial­ist in en­gi­neer­ing cus­tomized mi­crobes that has so far fo­cused on food and agri­cul­ture. The Boston-based com­pa­ny plans to in­te­grate Warp Dri­ve’s data­base of mi­cro­bial genome, as well as its search en­gine, with its own tech in pur­suit of new class­es of an­tibi­otics. Fi­nan­cials were not dis­closed.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN